MOTS-c: Clinical Guide for Prescribing Practices
MOTS-c is a mitochondria-derived peptide that plays a role in metabolic regulation, exercise mimicry, and cellular energy production. It has been studied for its effects on insulin sensitivity, fat metabolism, and exercise capacity. It represents a newer category of peptides focused on metabolic health and longevity.
Also Known As
How MOTS-c Works
MOTS-c is a 16-amino acid peptide encoded by the mitochondrial 12S rRNA gene that activates AMPK (AMP-activated protein kinase) through inhibition of the folate-methionine cycle, increasing intracellular AICAR accumulation [1]. AMPK activation triggers downstream metabolic reprogramming: enhanced glucose uptake via GLUT4 translocation, increased fatty acid oxidation, and improved insulin sensitivity independent of exercise [1]. MOTS-c also translocates to the nucleus under metabolic stress, directly regulating genes involved in antioxidant defense and metabolic homeostasis through interaction with ARE (antioxidant response element) transcription factors [3].
Clinical Evidence
A 2015 Cell Metabolism study demonstrated that MOTS-c prevents age-dependent and high-fat-diet-induced insulin resistance in mice, with effects comparable to exercise training on glucose homeostasis [1]. Circulating MOTS-c levels decline with age and correlate inversely with insulin resistance in human observational studies [4]. A 2021 Nature Communications study showed that exercise increases endogenous MOTS-c levels and that exogenous MOTS-c administration improves physical performance in aged mice [2]. Human pharmacokinetic and clinical efficacy data from controlled trials remain limited, though the mechanistic rationale from preclinical work is strong.
Clinical Uses
Patient Selection and Screening
Optimal candidates include patients with metabolic syndrome or prediabetes seeking non-pharmaceutical insulin sensitization [1], aging patients with documented decline in exercise capacity or mitochondrial function [2], and patients who cannot exercise due to physical limitations but would benefit from exercise-mimetic metabolic effects. Best positioned as part of a full metabolic optimization program rather than standalone therapy. Avoid in patients with active malignancy (AMPK activation effects on tumor metabolism are complex and not fully characterized). Monitor glucose closely in patients on insulin or sulfonylureas due to additive hypoglycemia risk.
Dosing and Administration
Subcutaneous injection: 5 to 10 mg administered 3 to 5 times per week [1]. Some protocols use daily dosing of 5 mg for initial 4-week loading, then reduce to 3 times weekly for maintenance. Treatment courses typically run 8 to 12 weeks with metabolic marker reassessment (fasting glucose, insulin, HOMA-IR, lipid panel) at 4 and 8 weeks. Administer in the morning to align with circadian metabolic rhythms. Injection sites should be rotated between abdominal and thigh subcutaneous tissue.
Route: Subcutaneous injection
Protocol notes: Typically administered via subcutaneous injection. Emerging protocols with limited clinical consensus.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
MOTS-c positions well within metabolic health and longevity programs as an exercise-mimetic peptide, appealing to an affluent patient demographic seeking cellular-level optimization [1]. The 8 to 12 week treatment courses with serial metabolic lab monitoring create recurring touchpoints and ancillary revenue. It differentiates practices from competitors focused solely on GLP-1 weight loss by offering a mitochondrial and metabolic optimization angle that appeals to the biohacker and longevity-minded patient population [2].
FDA Category Status
Expected to return to Category 1 per February 2026 HHS announcement
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe MOTS-c through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
What makes MOTS-c different from other peptides?
References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- Kim SJ, et al. The mitochondrial-derived peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metab. 2018;28(3):516-524.
- Zempo H, et al. Relation between MOTS-c level in blood and metabolic syndrome in Japanese elderly. J Gerontol A Biol Sci Med Sci. 2021;76(12):2096-2102.
Related Peptides in Metabolic & Longevity
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe MOTS-c Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe MOTS-c Through Karpa